CD274 and non-small cell lung carcinoma: Compared to the usual OS rate of 5% with standard chemotherapy, the 5-year OS rate of pembrolizumab treatment was 29.6% in NSCLC patients with a PD-L1 TPS of over 50% in the KEYNOTE-001 study (21).